Glucose metabolism disturbances and the risk of cardiovascular diseases;Zaburzenia gospodarki weglowodanowej a ryzyko chorób układu sercowo-naczyniowego

Advances in Clinical and Experimental Medicine

Volumn 15, Issue 5, 2006, Pages 911-916

  Derzhko, Roksolana ^a   Witkowska, Maria ^a  

^a Wroclaw Medical University Katedra i Klinika Kardiologii   (Poland)

Author keywords

Coronary heart disease; Disturbances of glucose metabolism

Indexed keywords

GLUCOSE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DISORDERS OF CARBOHYDRATE METABOLISM; EARLY DIAGNOSIS; FATALITY; HEART INFARCTION; HUMAN; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT;

EID: 37849187310     PISSN: 1230025X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Zimmet P: The burden of type 2 diabetes: are we doing enough? Diab Metab 2003, 29 (4 Pt 2), 609-618.
2. Harris MJ, Flegal KM, Cowie CC: Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance US adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diab Care 1999, 21, 518-528.
3. Tatoń J, Czech A, Berna M: Kardiodiabetologia, Via media, Gdańsk 2002.
4. Adamiec R, Zdrojowy K, Sutkowska E: WET-Diab - badanie populacyjne mieszkańców Wrocławia w kontekście chorobowości z powodu cukrzycy - doniesienie wstepne. Diabetologia Praktyczna 2004, 5, 189-194.
5. Haffner SM, Sehto S, Ronnemaa T: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339, 229-234.
6. Levitan EB, Song Y, Ford ES, Liu S: Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 2004, 164, 2147-2155.
7. Kowalska I, Prokop JB, Bachórzewska-Gajewska H: Disturbances of glucose metabolism in men reffered for coronary arteriography. Post-load glycemia as predictorfor coronary atherosclerosis. Diab Care 2001, 24, 897-901.
8. Bartnik M, Rydel L, Ferrari R: The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The EuroHeart Survey on diabetes and the heart. Eur Heart J 2004, 25, 1880-1890.
9. Brownlee M: Negative consequences of glycation. Metabolizm 2000, 49, 9-13.
10. Rosja A, Morale MA: Advanced glycation and endothelial functions: a link towards vascular complications in diabetes, Life Science, 2004, 76, 715-730.
11. Tan KCB, Chow WS, Ai VHG: Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diab Care 2002, 25, 1055-1059.
12. Basta G, Schmidt AM, de Caterina R: Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004, 63, 582-592.
13. Stern DM, Van SD, Yan SF, Schmit AM: Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev 2002, 1, 1-15.
14. Chavakis T, Bierhaus A, Nawroth PP: RAGE (receptor for advanced glycation end products): a central plater in the inflammatory response. Microbes and Infections 2004, 6, 1219-1225.
15. Inoguchi T, Li P, Umeda F: High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 2000, 49, 1939-1945.
16. Hu FB, Stampfer MJ, Haffner SM: Elevated pisk of cardiovascular disease priori to clinical diagnosis of type 2 diabetes. Diab Care 2002, 25, 1129-1134.
17. Norhammer A: Glucose metabolizm in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002, 359, 2140-2144.
18. Rodriguez BL, Lau N, Burchfiel CM: Glucose intolerance and 23-year risk of coronary heart disease and total mortality. The Honolulu Heart Program. Diab Care 1999, 22, 1262-1265.
19. DECODE Study Group: Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet 1999, 354, 617-621.
20. Hanefeld M, Fischer S, Julius U, Schyulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J (The DIS Group): Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1997, 39, 1577-1583.
21. De Vegt F, Dekker JM, Rube HG, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ: Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999, 42, 926-931.
22. Pyorala M, Miettinen H, Laakso M: Hiperinsulinemia predicts coronary heart disease risk in healthy middle-aged men. The 22-year follow-up results of the Helsinki Policemen Study. Circulation 1998, 98, 398-404.
23. Ginsberg HN: Insulin resistance and cardiovascular disease. J Clin Incest 2000, 106, 453-458.
24. Stuehlinger M, Abbasi F, Chu JW: Close relationship between insulin resistance and an endogenous nitric oxide inhibitor. JAMA 2002, 287, 1420-1426.
25. Marfella R: Effects of stress hyperglycemia on acute myocardial infarction. Diab Care 2003, 26, 3129-3133.
26. Franklin K, Goldberg RJ, Spencer F: Implications of diabetes in patients with acute coronary syndromes. Arch Intern Med 2004, 164, 1457-1463.
27. Pan XR, Li GW, Hu YH: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diab Care 1997, 20, 537-544.
28. Tuomilehto J, Lindstrom J, Eriksson JG: Prevention of type 2 diabetes mellitus by changes in lyfestyle among subjects with impaired glucose tolerance. N Engl J Med 2001, 344, 1343-1350.
29. Katzmarzyk FIT, Tremblay A, Petusse LI: The utility of international child and adolescent overweight guidelines for predicting coronary heart disease risk factors. J Clin Epidemiol 2003, 56, 456-462.
30. Yusuf S: Effects of an angiotensin-converting-enzym inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigation. N Engl J Med 2000, 342, 145-153.
31. Freeman DJ: Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001, 103, 357-362.